相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study
R. E. Pratley et al.
DIABETES OBESITY & METABOLISM (2014)
Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report
Yoko Noda et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
Asres Berhan et al.
BMC ENDOCRINE DISORDERS (2013)
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Recent advances in incretin-based therapies
David Russell-Jones et al.
CLINICAL ENDOCRINOLOGY (2012)
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
B. Eliasson et al.
DIABETOLOGIA (2012)
Non-high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training
Smita I. Negi et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2012)
Alogliptin as an initial therapy in patients with newly diagnosed, drug na⟨ve type 2 diabetes: a randomized, control trial
Eiji Kutoh et al.
ENDOCRINE (2012)
Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: The Atherosclerosis Risk in Communities (ARIC) carotid MRI study
Salim S. Virani et al.
ATHEROSCLEROSIS (2011)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences
Roberta Baetta et al.
DRUGS (2011)
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice
Nga N. Ta et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Differential Regulations of Lipid Profiles Between Japanese Responders and Nonresponders Treated with Pioglitazone
Eiji Kutoh
POSTGRADUATE MEDICINE (2011)
Alogliptin A Review of its Use in the Management of Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2010)
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
Joshua J. Neumiller
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION (2009)
Incretin-based therapies for type 2 diabetes mellitus
Julie A. Lovshin et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control A randomized, double-blind, placebo-controlled study
Ralph A. DeFronzo et al.
DIABETES CARE (2008)
A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes
Yunsheng Ma et al.
NUTRITION (2008)
Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice
B Ahrén et al.
ENDOCRINOLOGY (2005)
Japanese standard reference material for JDS Lot 2 haemoglobin A1c. II: Present state of standardization of haemoglobin A1c in Japan using the new reference material in routine clinical assays
M Tominaga et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2005)
分享论文
